Declines and pronounced regional disparities in prescription opioid use in the United States

Short title: Disparities in prescription opioids

Joshua D. Madera, MS¹, Amanda E. Ruffino, BA¹, Adriana Feliz, MBS¹, Kenneth L. McCall, PharmD², Brian J. Piper, PhD, MS¹,³*

¹Geisinger Commonwealth School of Medicine, Scranton, PA
²University of New England, Portland, ME
³Center for Pharmacy Innovation and Outcomes, Forty Fort, PA

*bpiper@som.gesiginer.edu; psy391@gmail.com

Abstract: 387 words
Figures: 3
Table: 1
Supplemental Table: 1
Abstract

Background. The United States (US) opioid epidemic is a persistent and pervasive public health emergency as it continues to claim the lives of Americans through addiction and overdose. There have been sustained efforts to reverse this iatrogenic crisis over the past decade. This study analyzed the changes in prescription opioid distribution for pain and identified regional differences between 2010 and 2019.

Methods and Findings. Opioid production data was obtained from the DEA’s annual production quotas. Total opioid production has decreased 41.5% from 2013 (87.6 morphine mg equivalent metric tons) to 2019 (51.3). Opioid distribution from 2010 to 2019 was collected for ten prescription opioids (codeine, fentanyl, hydrocodone, hydromorphone, meperidine, methadone, morphine, oxycodone, oxymorphone, and tapentadol) from the US Drug Enforcement Administration’s Automation of Reports and Consolidated Orders System. Regional variance was expressed as the ratio of the 95th to 5th percentiles of opioid distribution per state, corrected for population. The peak year for all ten prescription opioids was identified, individually, as between 2010 and 2013, except for codeine (2015). There was a 51.96% overall decrease in opioid distribution per capita with the largest decrease in Florida (-61.61%) and smallest in Texas (-18.64%). The largest quantities of opioid distribution were observed in Tennessee (520.70 morphine mg equivalent or MME per person) and Delaware (251.45) in 2011 and 2019. The smallest was Nebraska (153.39) in 2011 and Minnesota (90.49) in 2019. The highest to lowest state ratio of total opioid use, corrected for population, was sizable in 2011 (5.25) and 2019 (2.78). Similarly, the mean 95th/5th ratio was relatively stable in from 2011 (4.78 ±0.70) and 2019 (5.64±0.98). The 95th/5th ratio in 2019 was greatest for methadone (10.23) and oxymorphone (10.09) and smallest for morphine (2.20) and fentanyl (2.12). Southern states (e.g MS, TN, AL, AK, DE, and NC) had the highest per capita distribution for eight of the ten opioids in 2019. The strength of the correlation between per capita hydrocodone and codeine, and hydromorphone and codeine increased significantly from 2011 to 2019.

Conclusions. This study found a decline in total production and distribution for ten prescription opioids during the last half-decade. However, distribution was non-homogeneous at a state level. Analysis of regional differences revealed a three-fold difference in the 95th/5th percentile ratio between states which was unchanged over the past decade. Future research focused on identifying factors contributing to the observed regional variability could prove valuable to understanding, and potentially remediating, the pronounced disparities in prescription opioid use in the US.
Declines and pronounced regional disparities in prescription opioids in the United States
Joshua D. Madera, Amanda E. Ruffino, Adriana Feliz, Kenneth L. McCall, Brian J. Piper

Background
Drug overdoses are largely driven by opioids in the United States (US) and not only continue to escalate but also exceeded one-hundred thousand in one-year [1]. Despite knowledge of the risks of addiction and overdose, illicit and prescription opioids continue to have a strong presence throughout the US. The opioid prescription per capita increased by 7.3% between 2007 and 2012 with larger elevations in pain medicine (8.5%) and physical medicine/rehabilitation (12.0%) [2]. However, following an overall peak in 2011, and in 2012 for hospitals, there has been a gradual decline in opioid distribution [3,4]. Despite these reductions, the amount of opioids prescribed in 2015 [5] was almost three-fold higher than 1999 [6]. This upward trend may have been attributable to an increased prevalence of chronic pain, a limited knowledge regarding long-term opioid use, and capitalization on false claims regarding the non-addictive nature of opioids by pharmaceutical companies [7]. The morphine milligram equivalent (MME) per capita in 2016 in the US was 1,124 [3], which is appreciably higher than other developed countries [8] or the US Territories [9]. However, even this belies the pronounced variability between states. There was a five-fold difference between the lowest (North Dakota = 485) and highest (Rhode Island = 2,624) states [3]. Examination of individual opioids [10, 11] revealed a three-fold state-level difference for fentanyl [12], eighteen-fold for meperidine [13], and twenty-fold for buprenorphine [14].

This study aimed to identify patterns in the production and distribution between 2010 and 2019 of ten prescription opioids used primarily for pain. This range was chosen as it both includes and follows the implementation of legislative changes in most states intended to limit the distribution of opioids [12, 15] but is also prior to the COVID-19 pandemic and associated drug shortages [16]. Associations among state-level use of individual opioids were also determined. By identifying the state(s) with the highest and lowest declines in distribution as well as quantifying this variation, regional differences in efforts to combat the opioid epidemic can be examined.

Method
Procedures
Opioid production data were obtained from the US Drug Enforcement Administration’s (DEA) Production Quotas System [17], and opioid distribution data from their Automation of Reports and Consolidated Orders System (ARCOS). ARCOS is a publicly available reporting system mandated by the DEA that reports detailed and comprehensive drug information from manufacturing to distribution [18]. ARCOS data corresponds highly with state prescription drug monitoring programs [3, 19] and has been used in many prior investigations [3, 4, 9-16, 19, 20]. Information on ten Schedule II opioid prescription drugs used for the treatment of pain: codeine, fentanyl base, hydrocodone, hydromorphone, meperidine, methadone, morphine, oxycodone, oxymorphone, and tapentadol, were collected. Buprenorphine [14] was excluded because it is primarily employed for opioid use disorder. All procedures were approved by Geisinger and the University of New England’s Institutional Review Board.

Data Analysis
The oral MME for each opioid drug was determined using the appropriate multipliers: codeine 0.15, fentanyl base 75, hydrocodone 1, hydromorphone 4, meperidine 0.1, methadone 8, morphine 1, oxycodone 1.5, oxymorphone 3, and tapentadol 0.4 [3, 4] and summed for all ten opioids across all 50 states. Methadone [10], when utilized for the treatment of opioid use disorder, was excluded (note that there is no similar mechanism in the production quotas to differentiate subsequent pain versus narcotic treatment program use). The weight in grams of each opioid was obtained from ARCOS from 2010 to 2019 to isolate the peak opioid distribution year. Heat maps demonstrating the percent change across all 50 states per capita were produced using JMP. The per capita use of each opioid drug for each state was calculated using the respective population estimate from the American Community Survey [21]. Ratios for the highest to lowest states and for the 95th: 5th and 70th: 30th percentiles were calculated using these values [22]. Spearman correlations were calculated between each opioid for per capita distribution. The standard error of the mean (SEM) depicted variability. A Fisher r to Z transformation was completed to determine if the correlations differed between 2011 and 2019. All figures were constructed using the Graphpad Prism version 8.
Results

Production: Examination of total opioid production from 2010 (54.9 MME metric tons) to 2019 revealed a gradual increase from 2011 to 2012, followed by a steep increase from 2012 to 2013 (87.6 tons), which remained relatively steady until a pronounced decline from 2016 (85.2 tons) to 2017 (57.6 tons). There was a 39.8% reduction from 2016 until 2019 (51.3 tons). Meperidine (-60.0%), oxymorphone (-54.3%), morphine (-49.6%), fentanyl (-48.5%) and hydrocodone (-48.1%), exhibited pronounced declines. Oxycodone (-38.5%), codeine (-37.5%), hydromorphone (-32.9%), methadone (-30.1%), and tapentadol (-27.5%) had sizable but more modest reductions in opioid production (Figure 1A).

Distribution: Analysis of prescription opioid distribution from 2010 to 2019 identified 2011 as the peak year overall (Figure 1B). The peak for each drug was 2010 for methadone, oxycodone and meperidine; 2011 for hydrocodone and oxymorphone; 2012 for morphine and tapentadol; 2013 for hydromorphone and fentanyl; and 2015 for codeine. Since 2011 (23.2 MME metric tons), total opioid distribution for the ten opioids for pain has declined. From 2011 to 2019 (12.6 tons), a total decline in the opioid distribution of -45.4% was observed, with 2018 to 2019 showing a -11.3% decline.
Figure 1. Total opioid production (A) and distribution (B) in morphine mg equivalents (MME) across the United States from 2010 to 2019 as reported to the Drug Enforcement Administration’s Automated Reports and Consolidated Orders System of ten Schedule II opioids used primarily for pain.

Comparison of total opioid distribution per capita in 2011 (Figure 2A) and 2019 (Figure 2B) revealed an overall decrease (-51.96%), but also considerable state-level differences. In 2011, four states, Tennessee (520.70), Nevada (491.38), Delaware (476.15), and Florida (452.12), had significantly elevated levels of total opioid distribution relative to the national mean (284.34, \( p < 0.05 \)). However, only two states, Alabama (251.45) and Delaware (238.71) were significantly above the national average (162.09) in 2019. Forty-three states had an MME per capita > 200 in 2011 relative to only six in 2019 (\( \chi^2(1) = 54.78, p < .0001 \)). Four of these six were in the south-eastern (KT, TN) or south-central (AL, OK) US. Analysis of individual opioid distribution trends revealed codeine to have the largest per capita increase (+143.09%) and oxycodone the largest decrease (-50.09%) from 2011 to 2019. Furthermore, there was a 3.31 fold
difference between the highest (Florida = -61.61%) and lowest (Texas = -18.64%) states for the decline in opioid distribution. Figure 2E demonstrates the observed percent difference for a total opioid distribution during this period and showed that other states with sizable (> 50%) reductions were Nevada (-59.7%), Ohio (-57.4%), Tennessee (-55.2%), Maine (-54.4%), Oregon (-54.3%), and West Virginia (-50.9%).

**Figure 2.** Heat maps of the total opioid distribution in morphine mg equivalents (MME) per person across the United States in 2011 (A) and 2019 (B). Per person distribution was organized from largest to smallest values for 2011 with the 2019 per person distribution superimposed (C) with the values in 2019 and 2011 in parentheses after each state (* p < .05 versus the average states in 2011 (black font) and 2019 (green font)). Percent reduction in total opioid distribution from 2011 to 2019 (D).
C. Morphine Mg Equivalent per person

1. Tennessee (520.7, 233.3)
2. Nevada (491.4, 198.3)
3. Delaware (476.2, 251.5)
4. Florida (452.1, 173.6)
5. West Virginia (404.4, 186.6)
6. Oklahoma (381.5, 227.8)
7. Oregon (365.7, 167.0)
8. Alabama (361.1, 238.7)
9. Kentucky (359.5, 210.3)
10. Arizona (355.6, 181.5)

11. South Carolina (351.4, 188.9)
12. Maine (350.1, 159.6)
13. Michigan (312.4, 181.4)
14. Arkansas (309.8, 201.9)
15. Maryland (307.7, 197.8)
16. Pennsylvania (305.2, 183.3)
17. Missouri (300.1, 167.9)
18. Indiana (299.7, 168.7)
19. Ohio (299.1, 127.4)
20. New Mexico (289.9, 177.4)

21. Rhode Island (286.3, 187.4)
22. Washington (278.5, 152.0)
23. Louisiana (276.6, 174.2)
24. Montana (276.6, 151.3)
25. Connecticut (267.5, 186.7)
26. North Carolina (266.2, 194.4)
27. Utah (266.1, 239.6)
28. Kansas (263.9, 164.0)
29. New Jersey (262.7, 157.6)
30. New Hampshire (262.1, 169.8)

31. Alaska (249.1, 153.5)
32. Mississippi (248.5, 155.1)
33. Georgia (248.4, 168.7)
34. Colorado (243.6, 127.7)
35. Wisconsin (242.7, 124.5)
36. Idaho (239.3, 161.2)
37. Vermont (237.2, 169.8)
38. New York (235.4, 140.7)
39. California (230.6, 120.2)
40. Massachusetts (229.0, 136.4)

41. Hawaii (222.6, 112.5)
42. Wyoming (218.9, 145.0)
43. Virginia (212.0, 129.5)
44. South Dakota (191.3, 93.5)
45. Texas (169.3, 137.7)
46. Iowa (167.1, 92.3)
47. North Dakota (164.5, 92.7)
48. Illinois (160.4, 112.8)
49. Minnesota (154.5, 90.5)
50. Nebraska (153.4, 99.1)
Figure 3 shows the ratios between the 95th:5th percentiles for the population corrected distribution of each Schedule II opioid for 2011, the peak year, and 2019. This ratio was highest for oxymorphone (7.97) and meperidine (7.30) and smallest for codeine (2.40) and fentanyl (1.77) in 2011. The ratio was highest for methadone (10.23) and oxymorphone (10.09) and lowest for morphine (2.20) and fentanyl (2.12) in 2019. A comparison of the 95th:5th percentile ratios between 2011 (4.78 ±0.70) and 2019 (5.64 ±0.98) revealed a non-significant difference. Similarly, examination of the ratio of the maximum to minimum states was highest for oxymorophone (27.4) followed by meperidine (19.6), tapentadol (14.0), oxycodone (13.6), methadone (11.2), hydrocodone (9.2), hydromorphone (4.6), morphine (4.2), codeine (4.0) and fentanyl (2.5) in 2011 (mean = 11.0 ±2.4). The ratio was highest for oxymorphone (38.9), followed by methadone (30.3), meperidine (22.2), hydrocodone (13.4), tapentadol (12.3), codeine (9.8), oxycodone (6.1), hydromorphone (4.9), morphine (3.2), and fentanyl (3.1) in 2019 (mean = 14.4±3.7, t(9) = 1.45, p = .18). Eight states in the south had the highest per capita distribution for the ten opioids evaluated including Mississippi (fentanyl and hydromorphone), Tennessee (morphine and oxymorphone), Arkansas (meperidine), Alabama (hydrocodone), Delaware (oxycodone), and North Carolina (tapentadol) in 2019. The states with the lowest per
capita distribution included Texas (oxycodone and morphine), Hawaii (fentanyl and hydromorphone), and Minnesota (oxymorphone and tapentadol) in 2019 (Supplemental Table 1).

**Figure 3.** The 95\textsuperscript{th} to 5\textsuperscript{th} percentile ratio of the per person distribution per state for each of the prescription opioid as reported by the Drug Enforcement Administration’s Automated Reports and Consolidated Orders System (ARCOS) in 2011 and 2019.

Table 1 shows correlations in the MME per capita per state between each opioid. Oxycodone had the most significant correlations with the other opioids in both 2011 and 2019. In 2011, there were three, mostly moderate ($r = 0.35-0.69$), correlations between oxycodone with morphine, oxymorphone, and methadone. Moreover, there were also moderate associations between hydrocodone and meperidine, and between oxymorphone and tapentadol. In 2019, there were three moderate correlations between oxycodone with morphine, oxymorphone, and methadone. There were also moderate correlations between hydrocodone with meperidine and codeine. Fischer r to Z statistics were calculated to identify differences in the strength of the
correlations between opioids in 2011 relative to 2019. These analyses revealed a significant difference, i.e. an increase, in the magnitude of association between codeine and hydrocodone ($p < 0.05$), codeine and hydromorphone ($p < 0.01$), hydrocodone and methadone ($p < 0.05$), and methadone and oxycodone ($p < 0.05$). Comparisons between the averages of the correlations were then completed for each opioid with each other opioid. A significant difference was identified in the mean correlation between 2011 and 2019 for methadone ($p < 0.05$).
Table 1. Correlations for per capita state opioid distribution in 2011 and 2019. Boxes in blue and orange represent significant correlations between the opioids of < 0.05 and < 0.01, respectively. * Significance between Z scores when comparing 2011 and 2019 correlations. ** Significance between mean correlations between 2011 and 2019.

<table>
<thead>
<tr>
<th></th>
<th>A</th>
<th>B</th>
<th>C</th>
<th>D</th>
<th>E</th>
<th>F</th>
<th>G</th>
<th>H</th>
<th>I</th>
<th>Mean</th>
<th>Standard Error</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>codeine (A)</td>
<td>1.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.15</td>
<td>0.05</td>
</tr>
<tr>
<td>fentanyl (B)</td>
<td>0.31</td>
<td>1.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.23</td>
<td>0.04</td>
</tr>
<tr>
<td>hydrocodone (C)</td>
<td>0.17*</td>
<td>0.16</td>
<td>1.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.13</td>
<td>0.09</td>
</tr>
<tr>
<td>hydromorphine (D)</td>
<td>0.16*</td>
<td>0.28</td>
<td>-0.30</td>
<td>1.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.13</td>
<td>0.09</td>
</tr>
<tr>
<td>meperidine (E)</td>
<td>-0.10</td>
<td>0.10</td>
<td>0.62</td>
<td>-0.22</td>
<td>1.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.10</td>
<td>0.09</td>
</tr>
<tr>
<td>methadone (F)</td>
<td>0.08</td>
<td>0.06</td>
<td>-0.15*</td>
<td>0.40</td>
<td>-0.20</td>
<td>1.00</td>
<td></td>
<td></td>
<td></td>
<td>0.16</td>
<td>0.10</td>
</tr>
<tr>
<td>morphine (G)</td>
<td>0.33</td>
<td>0.39</td>
<td>0.24</td>
<td>0.29</td>
<td>0.18</td>
<td>0.35</td>
<td>1.00</td>
<td></td>
<td></td>
<td>0.26</td>
<td>0.07</td>
</tr>
<tr>
<td>oxycodone (H)</td>
<td>0.19</td>
<td>0.26</td>
<td>-0.12</td>
<td>0.44</td>
<td>0.02</td>
<td>0.66*</td>
<td>0.50</td>
<td>1.00</td>
<td></td>
<td>0.29</td>
<td>0.09</td>
</tr>
<tr>
<td>oxymorphone (I)</td>
<td>0.25</td>
<td>0.36</td>
<td>0.32</td>
<td>0.18</td>
<td>0.16</td>
<td>0.35</td>
<td>0.28</td>
<td>0.50</td>
<td>1.00</td>
<td>0.32</td>
<td>0.04</td>
</tr>
<tr>
<td>tapentadol (J)</td>
<td>0.01</td>
<td>0.14</td>
<td>0.24</td>
<td>-0.04</td>
<td>0.38</td>
<td>-0.08</td>
<td>-0.21</td>
<td>0.13</td>
<td>0.51</td>
<td>0.12</td>
<td>0.08</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>A</th>
<th>B</th>
<th>C</th>
<th>D</th>
<th>E</th>
<th>F</th>
<th>G</th>
<th>H</th>
<th>I</th>
<th>Mean</th>
<th>Standard Error</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>codeine (A)</td>
<td>1.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.08</td>
<td>0.08</td>
</tr>
<tr>
<td>fentanyl (B)</td>
<td>0.07</td>
<td>1.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.15</td>
<td>0.06</td>
</tr>
<tr>
<td>hydrocodone (C)</td>
<td>0.54*</td>
<td>0.33</td>
<td>1.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.12</td>
<td>0.12</td>
</tr>
<tr>
<td>hydromorphine (D)</td>
<td>-0.31*</td>
<td>0.14</td>
<td>-0.33</td>
<td>1.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.06</td>
<td>0.08</td>
</tr>
<tr>
<td>meperidine (E)</td>
<td>0.17</td>
<td>0.29</td>
<td>0.58</td>
<td>-0.07</td>
<td>1.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.17</td>
<td>0.09</td>
</tr>
<tr>
<td>methadone (F)</td>
<td>-0.10</td>
<td>-0.26</td>
<td>-0.45*</td>
<td>0.31</td>
<td>-0.39</td>
<td>1.00</td>
<td></td>
<td></td>
<td></td>
<td>-0.02**</td>
<td>0.10</td>
</tr>
<tr>
<td>morphine (G)</td>
<td>0.13</td>
<td>0.31</td>
<td>0.26</td>
<td>0.30</td>
<td>0.26</td>
<td>0.13</td>
<td>1.00</td>
<td></td>
<td></td>
<td>0.25</td>
<td>0.05</td>
</tr>
<tr>
<td>oxycodone (H)</td>
<td>0.10</td>
<td>0.05</td>
<td>0.02</td>
<td>0.25</td>
<td>0.21</td>
<td>0.39*</td>
<td>0.51</td>
<td>1.00</td>
<td></td>
<td>0.29</td>
<td>0.07</td>
</tr>
<tr>
<td>oxymorphone (I)</td>
<td>0.12</td>
<td>0.24</td>
<td>0.14</td>
<td>0.16</td>
<td>0.10</td>
<td>0.23</td>
<td>0.29</td>
<td>0.61</td>
<td>1.00</td>
<td>0.27</td>
<td>0.06</td>
</tr>
<tr>
<td>tapentadol (J)</td>
<td>-0.03</td>
<td>0.21</td>
<td>0.03</td>
<td>0.05</td>
<td>0.34</td>
<td>-0.02</td>
<td>0.02</td>
<td>0.43</td>
<td>0.49</td>
<td>0.17</td>
<td>0.07</td>
</tr>
</tbody>
</table>
Discussion

There are several findings from this investigation on the dynamic changes but also sizable regional variance in the distribution of prescription opioids in the US. This study determined that prescription opioids for pain have undergone a pronounced reduction over the past decade, which is congruent with and extends upon reports from earlier periods [2-6, 12]. This report identified a consistent decline in opioid distribution since 2011, the peak year [3]. There are a myriad of reasons that may explain the decline including increased awareness of the addictive nature of opioids [7], continued escalation in opioid-related overdose mortalities [1], and the increased government funding and resources resulting from the classification of the opioid crisis as a public health emergency [23]. Evidence has been more subtle or contradictory for any measurable impact of Prescription Drug Monitoring Programs [24, 25] or state opioid prescribing laws [12, 15].

Although there has been much prior attention to opioid distribution [2-6, 9-15], the changes in the production quotas have received limited quantitative attention. The total opioid production from 2010 to 2019 demonstrated a gradual increase from 2011 until 2016. There was a forty-percent decline after 2016. This reduction could be reflective of new recommendations such as the Department of Health and Human Services five-point strategy [23] to reduce factors contributing to the public health emergency, such as opioid production and distribution. Despite the observed reduction in most of the opioids examined, the overall production of codeine remained consistent between 2011 and 2019. This may be attributed to reasons such as the substitution of codeine and tramadol for hydrocodone for pain management, resulting in a steady demand for codeine production [2]. It did not escape notice that the total production quotas (Figure 1A) were about three-fold higher than opioid distribution (Figure 1B). One caveat is that distribution only included methadone when used for pain while the distribution included methadone that was subsequently employed for both pain and at narcotic treatment programs. By MME, methadone is by far the predominant prescription opioid in the US [3]. Examination of eleven opioids in ARCOS by zip code revealed that methadone could account for as much as four-fifths of the total [26]. The production of methadone for addiction treatment may account for a portion of the excess of production relative to distribution but a more important factor is the production quota is inclusive of opioids that are subsequently exported [27]. The total opioid distribution declined since 2011 despite the increase in total opioid production between 2011 to
2016. Oxycodone distribution was the most pronounced relative to the other nine opioids. However, oxycodone also demonstrated the largest decline in opioid distribution relative to its peak year. This appreciable decline could be due to factors such as pharmaceutical market changes as exemplified in the 2010 introduction of abuse-deterrent OxyContin (resistant to crushing or dissolving). Two years after the 2010 formulation change, the dispensing rate for extended-release oxycodone decreased 39% [28].

Analysis of the 95th:5th percentile ratios [22] was performed to identify the degree of variation between the highest and lowest per capita opioid distribution across the US where a higher 95th:5th ratio equates to greater variability. Although there have been overall reductions in opioid distribution, this measure of variation was consistent over the last decade. Similarly, six opioids, oxymorphone, meperidine, methadone, tapentadol, hydrocodone, and oxycodone, had ratios of the highest to lowest states > 5 in both 2011 and 2019. Oxymorphone, methadone, and meperidine had over twenty-fold highest to lowest ratios in 2019. While there are no federal quantity limits on Schedule II drug prescriptions, individual states and health insurance carriers can impose their own limitations regarding prescribing Schedule II drugs. These sub-federal restrictions on drug dispensation fall into several categories that involve drug days’ supply, dosage unit, and time a pharmacist can fill a prescription after it is issued [29, 30]. The formulation changes of oxycodone [28] and substitution of codeine for other opioids [29] could partially explain this substantial variability in their distributions. However, the federal reclassification of hydrocodone from a Schedule III to a Schedule II drug in 2014 [31] did not appreciably impact the variation (2011 percentile ratio = 6.11, 2019 ratio = 7.99). The high-potency opioid fentanyl had the lowest variation (2011 percentile ratio = 1.77, 2019 ratio = 2.12) which extends upon prior reports [11,12].

There may be some parallels between regional differences in prescription opioid use and drug overdoses. Drug overdose deaths have not homogeneously impacted the US [1]. Although death determination is a highly complicated process and data should be interpreted cautiously because of methodological differences between states [32], the eastern US has had more overdoses [1]. Similarly, opioid distribution was not homogeneous. Total per-capita opioid distribution from 2011 was significantly elevated in Tennessee, Nevada, Delaware, and Florida relative to the national mean. When analyzing the total per capita opioid distribution in 2019, only two states, Alabama and Delaware, were significantly higher than the national mean.
Further, when analyzing the data nationally, Florida [9] had the highest per capita opioid distribution decline while Texas [33] had the lowest decline. We can speculate that the general allowance of state discretion on what policies to implement and how to implement/enforce them may play a role in these observed differences in progress towards decreasing opioid distribution.

There were several positive correlations between opioid distribution per person per state. Interestingly, both 2011 and 2019 showed multiple associations with oxycodone. This finding may suggest that there may be a link between the tendency of being prescribed a correlated opioid medication, such as oxycodone, alongside the original prescribed opioid medication. Strong correlations were also found for codeine and hydrocodone, codeine and hydromorphone, hydrocodone and methadone, and methadone and oxycodone. As alluded to earlier, the shift away from prescribing methadone for analgesia may also explain our observation between methadone and hydrocodone exhibiting the strongest negative correlation in 2019. The prevailing indication for methadone production in 2019 [10] (opioid use disorder) is different from the indication for hydrocodone (pain). However, additional studies should explore the influence on treatment decisions at the patient level to further explore these opioid associations. It is very likely that medical specialty preferences exist for the choice of opioid medication based on knowledge of opioid pharmacology, comfort level, and experience. For example, otolaryngologists commonly prescribe hydrocodone and oxycodone, while family medicine physicians tend to prescribe buprenorphine [34-36].

While we successfully identified changes in Schedule II opioid production and distribution between 2011 and 2019 and greatly extended upon prior investigations [2, 3, 9-14, 23, 26, 33] to explore the substantial regional variation [37], this study was not without caveats. We reported a decline in opioid distribution beginning in 2011 based on the distribution rates of the opioids as mentioned earlier. However, other commonly prescribed opioids for opioid use disorder such as buprenorphine [14] were not included in our analysis and may have influenced the peak year of opioid distribution. In addition, ARCOS data does not account for Schedule IV or V opioids that could influence the total opioid distribution across the US [34]. For example, tramadol was moved to Schedule IV in 2014 [38]. The MMEs per capita would be even higher with the inclusion of additional non-Schedule II opioids. Moreover, the effects of racial, gender and socioeconomic disparities were not examined here but have been explored by others [39-43]. Stratifying data based on these demographics could identify more specific changes, and
continued disparities, in opioid distribution.

Overall, this study found dynamic changes in prescription opioid production and sizable but gradual reductions in distribution the US from 2010 to 2019. We speculate that this decline might result from factors such as increased government funding and resources, and an overall increased understanding of the addictive nature of opioids. More research on the prevalence of these opioids is necessary to weaken their grip on society. Further, the non-homogenous nature of opioid distribution and its effects on the population pose a barrier to continued efforts to one-day overcoming the US opioid epidemic. Further investigations of state and county level differences may inform the policies of opioid stewardship programs.

Acknowledgments

We would like to thank Geisinger Commonwealth School of Medicine for supporting this research and the Biomedical Research Club for technical assistance. We thank the Drug Enforcement Administration for making the Automated Reports and Consolidated Orders System dataset publicly available.
References


21. United States Census Bureaus, Accessed 11 November 2021 at:


**Supplemental Table 1.** Distribution of Schedule II opioids as reported by the Drug Enforcement Administration’s Automated Reports and Consolidated Orders System (ARCOS), corrected for population according to the annual American Community Survey, in 2011 (top) and 2019 (bottom). The abbreviation of the highest and lowest states is in superscript.

<table>
<thead>
<tr>
<th></th>
<th>70&lt;sup&gt;th&lt;/sup&gt; Percentile</th>
<th>30&lt;sup&gt;th&lt;/sup&gt; Percentile</th>
<th>70&lt;sup&gt;th&lt;/sup&gt; : 30&lt;sup&gt;th&lt;/sup&gt; Ratio</th>
<th>Maximum State</th>
<th>Minimum State</th>
<th>Max : Min Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>codeine</td>
<td>28.94</td>
<td>22.70</td>
<td>1.27</td>
<td>57.70&lt;sup&gt;MI&lt;/sup&gt;</td>
<td>14.28&lt;sup&gt;NY&lt;/sup&gt;</td>
<td>4.04</td>
</tr>
<tr>
<td>fentanyl</td>
<td>0.92</td>
<td>0.70</td>
<td>1.32</td>
<td>1.17&lt;sup&gt;SD&lt;/sup&gt;</td>
<td>0.47&lt;sup&gt;HI&lt;/sup&gt;</td>
<td>2.50</td>
</tr>
<tr>
<td>hydrocodone</td>
<td>78.77</td>
<td>43.80</td>
<td>1.80</td>
<td>163.93&lt;sup&gt;TN&lt;/sup&gt;</td>
<td>17.78&lt;sup&gt;NJ&lt;/sup&gt;</td>
<td>9.22</td>
</tr>
<tr>
<td>hydromorphine</td>
<td>2.72</td>
<td>2.01</td>
<td>1.35</td>
<td>4.84&lt;sup&gt;DE&lt;/sup&gt;</td>
<td>1.05&lt;sup&gt;HI&lt;/sup&gt;</td>
<td>4.61</td>
</tr>
<tr>
<td>meperidine</td>
<td>4.03</td>
<td>2.23</td>
<td>1.81</td>
<td>13.89&lt;sup&gt;AR&lt;/sup&gt;</td>
<td>0.71&lt;sup&gt;MN&lt;/sup&gt;</td>
<td>19.56</td>
</tr>
<tr>
<td>methadone</td>
<td>29.70</td>
<td>17.16</td>
<td>1.73</td>
<td>64.57&lt;sup&gt;ME&lt;/sup&gt;</td>
<td>5.79&lt;sup&gt;SD&lt;/sup&gt;</td>
<td>11.15</td>
</tr>
<tr>
<td>morphine</td>
<td>44.63</td>
<td>31.99</td>
<td>1.40</td>
<td>81.88&lt;sup&gt;OR&lt;/sup&gt;</td>
<td>19.77&lt;sup&gt;TX&lt;/sup&gt;</td>
<td>4.14</td>
</tr>
<tr>
<td>oxycodone</td>
<td>122.84</td>
<td>84.30</td>
<td>1.46</td>
<td>304.57&lt;sup&gt;DE&lt;/sup&gt;</td>
<td>22.44&lt;sup&gt;IL&lt;/sup&gt;</td>
<td>13.57</td>
</tr>
<tr>
<td>oxymorphone</td>
<td>3.31</td>
<td>1.74</td>
<td>1.91</td>
<td>10.42&lt;sup&gt;TN&lt;/sup&gt;</td>
<td>0.38&lt;sup&gt;MN&lt;/sup&gt;</td>
<td>27.42</td>
</tr>
<tr>
<td>tapentadol</td>
<td>8.59</td>
<td>4.58</td>
<td>1.87</td>
<td>19.60&lt;sup&gt;AL&lt;/sup&gt;</td>
<td>1.40&lt;sup&gt;MN&lt;/sup&gt;</td>
<td>14.00</td>
</tr>
<tr>
<td></td>
<td>70th Percentile</td>
<td>30th Percentile</td>
<td>70th : 30th Ratio</td>
<td>Maximum State</td>
<td>Minimum State</td>
<td>Max : Min Ratio</td>
</tr>
<tr>
<td>------------------</td>
<td>-----------------</td>
<td>-----------------</td>
<td>-------------------</td>
<td>---------------</td>
<td>---------------</td>
<td>----------------</td>
</tr>
<tr>
<td>codeine</td>
<td>14.48</td>
<td>10.71</td>
<td>1.35</td>
<td>57.63&lt;sup&gt;UT&lt;/sup&gt;</td>
<td>5.87&lt;sup&gt;CO&lt;/sup&gt;</td>
<td>9.82</td>
</tr>
<tr>
<td>fentanyl</td>
<td>0.36</td>
<td>0.28</td>
<td>1.29</td>
<td>0.55&lt;sup&gt;MS&lt;/sup&gt;</td>
<td>0.18&lt;sup&gt;HI&lt;/sup&gt;</td>
<td>3.05</td>
</tr>
<tr>
<td>hydrocodone</td>
<td>38.49</td>
<td>20.38</td>
<td>1.89</td>
<td>78.39&lt;sup&gt;AL&lt;/sup&gt;</td>
<td>5.84&lt;sup&gt;NJ&lt;/sup&gt;</td>
<td>13.42</td>
</tr>
<tr>
<td>hydromorphone</td>
<td>1.64</td>
<td>1.24</td>
<td>1.32</td>
<td>3.41&lt;sup&gt;MS&lt;/sup&gt;</td>
<td>0.70&lt;sup&gt;HI&lt;/sup&gt;</td>
<td>4.87</td>
</tr>
<tr>
<td>meperidine</td>
<td>0.66</td>
<td>0.33</td>
<td>1.99</td>
<td>2.48&lt;sup&gt;AK&lt;/sup&gt;</td>
<td>0.11&lt;sup&gt;RI&lt;/sup&gt;</td>
<td>22.17</td>
</tr>
<tr>
<td>methadone</td>
<td>28.56</td>
<td>15.68</td>
<td>1.82</td>
<td>86.88&lt;sup&gt;RI&lt;/sup&gt;</td>
<td>2.87&lt;sup&gt;WY&lt;/sup&gt;</td>
<td>30.22</td>
</tr>
<tr>
<td>morphine</td>
<td>22.94</td>
<td>16.33</td>
<td>1.40</td>
<td>34.33&lt;sup&gt;TN&lt;/sup&gt;</td>
<td>10.85&lt;sup&gt;TX&lt;/sup&gt;</td>
<td>3.16</td>
</tr>
<tr>
<td>oxycodone</td>
<td>68.83</td>
<td>53.59</td>
<td>1.28</td>
<td>109.65&lt;sup&gt;DE&lt;/sup&gt;</td>
<td>17.89&lt;sup&gt;TX&lt;/sup&gt;</td>
<td>6.13</td>
</tr>
<tr>
<td>oxymorphone</td>
<td>0.69</td>
<td>0.32</td>
<td>2.16</td>
<td>2.71&lt;sup&gt;TN&lt;/sup&gt;</td>
<td>0.07&lt;sup&gt;MN&lt;/sup&gt;</td>
<td>38.92</td>
</tr>
<tr>
<td>tapentadol</td>
<td>6.64</td>
<td>3.94</td>
<td>1.68</td>
<td>15.28&lt;sup&gt;NC&lt;/sup&gt;</td>
<td>1.24&lt;sup&gt;MN&lt;/sup&gt;</td>
<td>12.31</td>
</tr>
</tbody>
</table>